Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Running

ON-TRACT OligoNucleotide Technologies for Rapid Advancement of Cancer Therapies

Coordinator
University of Southampton, United Kingdom
Runs
1 January 2026 to 31 December 2029
Status
Running
EU funding
€4.4m
Total cost
—
Partners
16 organisations in 6 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101227456

What the project is doing

In the project's own words, from its summary on CORDIS.

ON-TRACT focuses on advancing oligonucleotides (ONs) in medicinal chemistry to tackle urgent challenges in treating lung cancer, B-cell malignancies, and chronic inflammation. ONs are powerful tools for gene-specific therapy, yet their clinical use is hindered by challenges such as limited stability, inefficient delivery, and off-target effects. Since 2000, more than a dozen Nobel Prizes related to oligonucleotides in Chemistry or Medicine/Physiology, such as CRISPR-CAS9, telomers, DNA replication, RNA vaccines or micro-RNAs, highlight their transformative potential, but further innovation is essential to realise their full impact.

Our consortium, consisting of 10 academic research groups, 4 companies, 1 hospital, and 1 non-profit organisation, will address these limitations through an interdisciplinary approach. Key objectives include developing sustainable chemical synthesis methods to reduce environmental impact, advancing delivery technologies such as monoclonal antibodies, dendrimers, and inhalers for targeted and efficient delivery, and employing organoids as ethical, human-relevant alternatives to animal models for testing.

By integrating expertise in chemistry, biology, advanced delivery systems and medicine, the project aims to create a robust framework for oligonucleotide-based therapies. This holistic strategy will not only advance the development of innovative treatments for severe diseases but also set new standards for sustainability and ethical testing in medicinal chemistry. In addition, we will train 13 highly skilled researchers, ready to take on Europe’s challenges in the life sciences sector; our interdisciplinary and intersectoral training programme will give all ON-TRACT researchers the skills needed for a successful career in any sector.

Topics

Who is involved

OrganisationCityCountryRole
University of SouthamptonSouthamptonUnited KingdomCoordinator
Universiteit GentGentBelgiumParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite D'aix MarseilleMarseilleFranceAssociatedpartner
Universita Degli Studi Di UdineUdineItalyParticipant
Institute of Organic Chemistry - Polish Academy of SciencesWarszawaPolandParticipant
Instytut Biologii Doswiadczalnej Im. M. Nenckiego Polskiej Akademii NaukWarszawaPolandAssociatedpartner
Astrazeneca ABSodertaeljeSwedenAssociatedpartner
Karolinska InstitutetStockholmSwedenParticipant
PeptiSystems ABUppsalaSwedenAssociatedpartner
Region GävleborgGävleSwedenAssociatedpartner
Rise Research Institutes of Sweden ABBorasSwedenParticipant
Strike Pharma ABUppsalaSwedenAssociatedpartner
Uppsala UniversitetUppsalaSwedenParticipant
CPI Innovation ServicesTeessideUnited KingdomAssociatedpartner
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI